Navigation Links
Experimental Psoriasis Drug Bests Older Treatment
Date:10/27/2011

By Serena Gordon
HealthDay Reporter

WEDNESDAY, Oct. 26 (HealthDay News) -- An experimental psoriasis treatment performed significantly better than the commonly prescribed medication methotrexate in a new clinical trial.

The drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate. But serious side effects were more common among the briakinumab users.

"Very high levels of response" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.

Results of the study are published in the Oct. 27 issue of the New England Journal of Medicine. The study was funded by the drug's manufacturer, Abbott Laboratories.

Psoriasis affects about 5 million Americans, according to the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The disease causes patches of thick, red, inflamed skin that have silvery scales. Psoriasis can affect any part of the body, including the skin, nails, genitals and inside the mouth, according to NIAMS.

The current study included 317 people with moderate to severe psoriasis. The study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.

Nearly half of the study participants were randomly selected to receive injections of briakinumab at a dose of 200 milligrams (mg) for the first and fourth week of the study, and 100 mg at week eight and every four weeks thereafter. The study lasted one year. The remaining volunteers were given between 5 mg and 25 mg of oral methotrexate weekly.

After six months, nearly 82 percent of those in the briakinumab group had at least a 75 percent improvement in the psoriasis area-and-severity index (PASI), a commonly used measurement to assess the severity of psoriasis. Slightly less than 40 percent of those on methotrexate had a 75 percent improvement in their PASI score, according to the study.

After a year, about 66 percent of those taking briakinumab had a 75 percent improvement in their PASI score compared to almost 24 percent for those on methotrexate, according to the study.

Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.

More serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent). There were also two cases of cancer in people taking briakinumab and none in the methotrexate group. However, the researchers said these differences weren't statistically significant.

"Cancer risk is extremely hard to define, and this study was not powered to detect any difference in the risk of developing a malignancy," said Bebo.

He said that in an earlier trial of briakinumab, some unexplained major adverse cardiac events occurred. At the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research. In the current study, no serious cardiovascular events were reported.

Of the increased infections and cancers, Reich said, "Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug."

Research on briakinumab is continuing. An ongoing three-year trial involves 248 people from the current study.

For people living with psoriasis, Bebo said the message from this study is that "dramatic progress has been made from where we were just five years ago."

More information

Learn more about psoriasis treatments from the National Psoriasis Foundation.

SOURCES: Kristian Reich, M.D., professor, dermatology, University of Gottingen, and managing partner, Dermatologikum Hamburg, Germany; Bruce Bebo, Ph.D., director, research and medical programs, National Psoriasis Foundation, Portland, Ore.; Oct. 27, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Psoriasis Drug Bests Older Treatment
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: